Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The voltage-gated sodium channel protein type 9 subunit alpha (NaV1.7) is the pore-forming α subunit of the NaV1.7 channel, encoded by the SCN9A gene. It plays a critical role in generating and conducting action potentials in excitable cells, especially neurons involved in pain sensation (nociceptors). Mutations in SCN9A are linked to several human disorders, including paroxysmal extreme pain disorder, congenital insensitivity to pain, and anosmia.
Blocker of voltage-gated sodium channels, inhibiting neuronal excitability
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-gated sodium channel protein type 9 subunit alpha (NaV1.7).